Terwey et al developed a modified European Group for Blood and Marrow Transplantation Risk Score (mEBMT) for evaluating an adult with Acute Lymphoblastic Leukemia prior to a bone marrow transplant. The authors are from Universitatsmedizin Berlin and Stadtisches Klinikum Gutersloh in Germany.
Patient selection: adult of ALL
Parameters:
(1) age in years
(2) disease stage (with respect to complete remission)
(3) donor type
(4) gender combination
|
Parameter |
Finding |
Points |
|
age of years |
< 20 years of age |
0 |
|
|
20 to 40 years of age |
1 |
|
|
> 40 years of age |
2 |
|
disease stage |
first complete remission |
0 |
|
|
second complete remission or higher |
1 |
|
|
no complete remission |
2 |
|
donor type |
matched, related donor |
0 |
|
|
other |
1 |
|
gender combination |
female to male |
1 |
|
|
other (female to female, male to male, male to female) |
0 |
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 6
• The higher the score the worse the survival.
|
mEBMT |
Percent 10 Year Survival |
|
0 or 1 |
58% |
|
2 |
38% |
|
3 or 4 |
24% |
|
5 or 6 |
very low |
Specialty: Hematology Oncology, Surgery, general
ICD-10: ,
